REVIEW

The genetics and biomechanics of thoracic aortic diseases

Amer Harky\textsuperscript{1}, Ka Siu Fan\textsuperscript{2} and Ka Hay Fan\textsuperscript{3}

\textsuperscript{1}Department of Cardiothoracic Surgery, Liverpool Heart and Chest, Liverpool, UK
\textsuperscript{2}St. George’s Medical School, University of London, London, UK
\textsuperscript{3}Faculty of Medicine, Imperial College London, London, UK

Correspondence should be addressed to A Harky: aaharky@gmail.com

Abstract

Thoracic aortic aneurysms and aortic dissections (TAAD) are highly fatal emergencies within cardiothoracic surgery. With increasing age, thoracic aneurysms become more prevalent and pose an even greater threat when they develop into aortic dissections. Both diseases are multifactorial and are influenced by a multitude of physiological and biomechanical processes. Structural stability of aorta can be disrupted by genes, such as those for extracellular matrix and contractile protein, as well as telomere dysfunction, which leads to senescence of smooth muscle and endothelial cells. Biomechanical changes such as increased luminal pressure imposed by hypertension are also very prevalent and lead to structural instability. Furthermore, ageing is associated with a pro-inflammatory state that exacerbates degeneration of vessel wall, facilitating the development of both aortic aneurysms and aortic dissection. This literature review provides an overview of the aetiology and pathophysiology of both thoracic aneurysms and aortic dissections. With an improved understanding, new therapeutic targets may eventually be identified to facilitate treatment and prevention of these diseases.

Introduction

Thoracic aortic aneurysms and dissections are highly lethal aortic diseases that can present as emergencies and will require urgent surgical treatment: while the majority of patients with dissection and ruptures will not survive without surgical repair, post-operative mortality may remain as high as 25%, in addition to serious complications such as stroke and spinal cord injury (1). While surgical advancements have improved morbidity and mortality rates over time, non-surgical management and preventative action can further reduce the burden of TAAD on our society. Of the 5160 deaths in the United Kingdom attributed to aortic aneurysms and dissections in 2017, the majority occurred in the elderly: with the rise of senescence, it is important to address the physiological factors that contribute to these aortic diseases early to prevent morbidity and mortality (2).

Both diseases within TAAD often occur concurrently and both owe its aetiology to aortic wall dysfunction (3). The wall dysfunction also predisposes the formation of thoracic aortic aneurysms (TAA), which naturally enlarge and further increase the risk of thoracic aortic dissection (TAD) (3). At the centre of both diseases lies the aortic wall, and like arteries, it is divided into tunica intima, media and adventitia. Thoracic aortic aneurysms affect all three layers of the vessel and is applicable to any dilatation of over 1.5 times its normal size anywhere from the aortic root to the beginning of abdominal aorta (4, 5). TAA's most commonly affect the aortic root and
ascending aorta (60%) but can also affect other segments such as descending aorta (35%) and aortic arch (<10%) (6). Despite being similar pathologies and sharing some aetiologies, such as connective tissue degeneration and biomechanical changes, TAA distinguishes itself from the signature inflammatory changes in abdominal aortic aneurysms (AAAs) with its heavier genetic involvements (5, 7). Alongside well-known genetic syndromes, there are at least 15 highly penetrant genetic mutations that predisposes TAAD (3, 8). While the eventual outcome is the loss of aortic shape and gradual development into TAAD, dissection can also develop independently of aneurysms (8). TAD occurs when there is intramural haemorrhaging and propagation between the intimal and medial layer of the aorta, allowing blood to pool within a false lumen. Like TAA, TAD can occur anywhere along the aortic arch, ascending and descending aorta and are denoted by DeBakey or Stanford classification systems (8). As expected, aetiology of TAA and TAD overlaps and are broadly classified by mechanisms: wall stress and medial degeneration. Increased wall stress, most commonly due to hypertension, is known to cause both TAA and TAD is prevalent in two-thirds of all patients with TAD.

Conditions such as Marfan syndrome, Ehlers–Danlos syndrome, Turner syndrome and aortic inflammation affect aortic wall integrity and cause medial wall degeneration, contributing to the development of TAD (8). Regardless of aetiology, both diseases can present similarly as a severe central chest pain that radiates to the back and calls for immediate treatment (1).

Typically, the first step in managing TAAD in stable patients is to slow the worsening of aneurysm or dissection through controlling their risk factors. This involves optimising the blood pressure and lipid control as well as making lifestyle changes such as smoking cessation and avoidance of strenuous exercises (8). This can also be achieved medically: through the use of β-blockers, angiotensin-II receptor blockers and angiotensin-converting enzyme inhibitors, TAAD can also be managed medically, the effects however were based on relatively small studies (8, 9, 10). Even with optimised management, the thoracic aorta can continue to grow and will experience a sharp increase in risk of rupture, dissection and surgical mortality once it reaches 6 to 7 cm in diameter (8). Unlike other variants, type A aortic dissection is an emergency: almost 48.6% mortality occurring before hospital assessment and intervention only narrowly improves patient survival rate (3, 11). This provides the basis for regular monitoring of TAAD and early prophylactic surgical repair for the best outcome. A myriad of surgical approaches are employed in repairing TAAD; ascending and aortic arch TAAD are typically treated with open repairs, whereas descending TAAD are treated with endovascular stent-grafts.

Like any other disease, prevention is superior to treatment and a better understanding of TAAD will improve upon our control over disease development and progression, delivering better patient outcomes. The underlying aetiology of TAAD development can be broadly classified into several causes: genetic, telomere, biomechanical and inflammatory (Fig. 1). To understand the aetiology governing the mechanisms of TAAD formation, there is active research into probable causes such as genetic association, telomere length, biomechanics and inflammation. This literature review will explore the interaction and evidence behind these factors that contribute to the formation and progression of thoracic aortic aneurysms and dissections.

Genetics of aortic aneurysm and dissection

With TAAD being the result of dysfunctional physiology of the aortic wall, it follows that there are genetic factors involved in altering the wall function and predisposing patients to TAAD. There are several known genetic causes that can cause medial degeneration which in turn precipitate the formation of TAAD, with the most famous being Marfan, Loeys–Dietz and Ehler–Danlos syndrome (12). As many patients with these syndromes develop TAAD, they are noted to have heritable or familial forms of TAAD to signify their background aetiology. While up to 20% of individuals with a family history of TAAD do not have a known syndrome we only know of a handful of associated genes, with many more yet to be uncovered (3, 11, 12).

Genetic syndromes and TAAD

Syndromic causes are the chief associated or causative pathologies behind the genetics of TAAD: all identified syndromes have effects on vessel integrity and the associated TAAD sudden deaths commonly plague these patients. Marfan syndrome (MFS, OMIM 154700) is an autosomal dominant connective tissue disorder that typically affects the skeletal and cardiovascular system (12,13). While MFS is associated with Marfan locus on chromosome 15, presentation remains highly variable (14, 15). Central to its pathophysiology is the defect in fibrillin-1 gene (FBN1) which is responsible for up to...
93% of all MFS cases; FBN1 at 15q15–q21.1 encodes for fibrillin-1, a glycoprotein within extracellular matrix (ECM) microfibril such as elastic fibres of the medial wall of the aorta and is abnormally metabolised in most MFS patients (14, 15, 16). This indirectly involves TGF-β, a molecule that contributes to TAAD development through regulating MMP activity and extracellular matrix breakdown. FBN1 regulates TGF-β receptors and serves to inhibit TGF-β, hence, defects in FBN1 indirectly raises TGF-β and lead to increased TAAD formation. Despite uncovering pathophysiology of FBN1, approximately 10% of Marfan syndrome cases are caused by genetically unknown origins (17). Similar to FBN1, defects in FBN2 causes a Marfan-like syndrome called Beals syndrome or congenital contractural arachnodactyly. This gene lies on chromosome 5q23-31 and also introduces a similar instability through affecting ECM microfibrils (18, 19).

Another commonly associated pathology is Ehlers-Danlos syndrome (EDS) characterised by fragility and rupture of arteries, intestines and uterus (20). Vascular EDS (type IV, OMIM# 130050) has the worst prognosis of all EDS types due to vascular complications with type III collagen dysfunction. This is an autosomal dominant pathology that primarily affects the ECM of the cardia and vasculature through defective type III procollagen gene (COL3A1), which is responsible for almost all cases (21). Type IV is the only to affect type III procollagen and is associated with a history of sudden deaths in close relatives (21). As the elastic property of vessel walls are dependent on the abundance and function of type III collagen, disruption in procollagen is responsible for their generalised vascular fragility and predisposition of TAAD.

Similarly, patients with Turner syndrome (TS) are predisposed to a myriad of cardiovascular malformations: aortic dissection, coarctation, congenital bicuspid aortic valve, persistent left superior vena cava and various left-sided malformations are common and lead to 41% of cardiovascular events in TS patients (22). Aortic root dilatation is often present and thought to be blood pressure dependent, with it eventually forming aneurysms and dissections (22, 23). Hypertension aside, congenital bicuspid aortic valves, coarctation and short stature of female TS patients also predisposes aortic dilatation and dissection (22, 23, 24). Ascending aorta diameter in short female TS patients are significantly wider than healthy cohorts and is responsible for increased incidence of up

Figure 1
Overview of various contributing factors towards formation of thoracic aneurysm (44).
to 618 cases/100,000 woman-years compared to under 3/100,000 annually (25).

Loeys–Dietz syndrome (LDS) is a relatively new autosomal dominant syndrome that describes the effects associated with mutations in transforming growth factor beta receptor genes 1 and 2 (TGFBR1/TGFBR2) (26). LDS presentation can vary, with type 1 being Marfan-like and type 2 similar to EDS. Regardless, loss of TGFβ function and subsequent dysregulated signalling pathways are thought to affect TAAD development through alteration of collagen and elastin metabolism.

Another relatively rare condition, multisystemic smooth muscle dysfunction syndrome, is a defect in ACTA2 that manifests as decreased contractility of smooth muscle cells (SMC) (27, 28). In one study, a defective ACTA2 is seen in 14 of 98 unrelated TAAD families, of which most of the individuals died of dissection (29). Its association with TAAD is proposed to be defective α-actin polymerisation which affects actin fibre stability in SMC of thoracic aorta (28). The commonly known syndromic genes and pathophysiology are displayed in Table 1.

**Non-syndromic genetic association with TAAD**

Many patients do not have a syndromic cause but present with a strong familial history and some are regarded as a type called familial TAAD. While syndromic genes provide a myriad of clinical presentation and signs, individual genes are more difficult to identify. Through genetic screening of families with high TAAD incidence, some genes have been identified to be common among these families, but there are also unique mutations only present in selected families. However, not all the identified genes have been thoroughly investigated to elucidate their exact pathophysiology. The various genetic defects affect the physiology central to TAAD such as impairment of SMC function by FOXE3 and MAT2A or ECM disruption by MFAP5 (30, 31, 32). The known non-syndromic genes and pathophysiology are displayed in Table 2.

**Telomere and its role in genetic disruption**

With such prominent role of genetics within the formation of TAAD, it is also important to consider the regulation of genetic materials which governs the underlying cellular processes. Genetic stability is maintained by telomeres which are tandem DNA repeat sequences that stabilises chromosomes (44). While telomeres serve their function, their length is reduced after every replication, essentially giving each chromosome a limited lifespan. This represents the biological senescence of cells and is generally limited to approximately 50 divisions. Telomere shortening in age-related diseases such as cardiovascular diseases have been proven to reflect cellular turnover and shows potential within TAAD cases (44). The biological ageing effect of telomere attrition can also be caused by oxidative stress, damaging repair mechanisms present in certain cells lineages where telomerase restores the tandem repeat sequences.

Preclinical studies have identified age-related endothelial cell (EC) and SMC dysfunction that contributes to the vascular damage seen in AAA (44). Several stress-induced senescence markers and vascular mediators were studied in mice and shown to have a role in regulating telomere length (44, 45, 46). With similar mechanics at play in AAA, telomere shortening in EC, SMC and leukocytes may also be crucial to TAAD development (44). However, there is currently a lack of thoracic aorta specific research and much of our understanding is built upon our knowledge on AAA.

**Endothelial cells and smooth muscle cells**

The structural integrity of aorta is heavily dependent on the physiology of EC and SMC: with EC exerting influence over development of SMC, they regulate the vascular tone, blood pressure and vasculogenesis (47, 48). A study by Cafueri et al. identified that patients with AAA had significantly shorter telomere lengths in the EC and SMC when compared to control groups (49). The effects of telomerase in EC of abdominal aorta has been studied by Dimitriou et al. associating attenuated telomerase expressions with AAA (50). Their findings are in line with a study by Okuda et al. who found that higher rates of telomere attrition is associated with accelerated senescence of EC (51). Okuda et al. also identified differences in the rate of telomere shortening between various segments of the abdominal aorta and attributed the difference in cell turnover to shear wall stress of the distal segments. Similarly, Wilson et al. showed that telomeric DNA is significantly reduced in AAA biopsies compared to normal aortas of cadaveric donors (52). As most of the current literature focuses on AAA specifically, Blunder et al. investigated telomeres in TAA: telomeric lengths of SMC in TAA aortic valves demonstrated to both reduce proliferation and migration of aneurysmal SMCs (53). Their demonstration of telomere shortening in TAA compared to controls also corroborates with the available literature on AAA, supporting potentially similar telomere biology at play.
Leukocytes

Another significant class of cells affected by dysregulation of telomere are leukocytes: abnormality with inflammatory effector cells may explain TAAD pathogenesis. Multiple studies have identified association between leukocyte telomere length and vascular degeneration, as well as a varied relationship with TAAD. There is contrasting evidence on leukocyte telomere lengths as both lengthening and shortening have been observed in TAA. Huusko et al. demonstrated lengthened leukocyte telomere in TAA and was accompanied by a statistically significant rise in telomerase expression as a compensatory mechanism (54). This contrasts with the work by Balistreri et al. and Blunder et al. who identified shortened telomere lengths in TAA (53, 55). Similarly, Yan et al. found that leukocyte telomere in TAD is consistently shorter than controls across various age groups (P<0.05) and suggests potential to predict aortic dissections (56). With the conflicting evidence on TAAD, and lack of large studies, more research is required to determine the nature of relationship between leukocyte telomere and TAAD development.

Mechanobiology of aorta

Mechanobiology of the aortic wall is a crucial aspect of TAAD development as it is chiefly mediated by medial degeneration. The tunica media layer is mostly occupied

Table 1  Syndromic genetic associations with thoracic aortic aneurysms and dissections.

| Syndrome | Gene loci | Presentation | Pathophysiology |
|----------|-----------|--------------|-----------------|
| Congenital contractural arachnodactyly (33) | FBN2 | TAAD | Disruption of ECM microfibril through fibrillin-2 |
| Ehlers-Danlos syndrome (EDS) type IV (20) | COL3A1 | TAAD | Defective type III procollagen disrupts collagen III deposition and function |
| Loeys-Dietz syndrome (26) | TGFBR1, TGFBR2 | TAAD | Alters TGF-β signalling dysregulates collagen and elastin physiology |
| Marfan syndrome (14, 15) Multisystemic smooth muscle dysfunction syndrome (27, 28) Turner syndrome (22) | FBN1, ACTA2 | Partial or complete loss of X chromosome | Disruption of ECM microfibril through fibrillin-1 |

| Syndrome | Gene loci | Presentation | Pathophysiology |
|----------|-----------|--------------|-----------------|
| Marfan syndrome (14, 15) Multisystemic smooth muscle dysfunction syndrome (27, 28) Turner syndrome (22) | FBN1, ACTA2 | Partial or complete loss of X chromosome | Defective α-actin affects aortic SMC function |
| | | TAAD | Congenital cardiac and vascular malformation changes haemodynamics |

Table 2  Non-syndromic genetic associations with thoracic aortic aneurysms and dissections.

| Gene loci | Association | Presentation | Pathophysiology |
|-----------|-------------|--------------|-----------------|
| FBN1 (16) | Present in 3.9% of non-syndromic TAD | TAAD | Affect ECM microfibrils and causes sporadic TAD in non-Marfan patients |
| FOXE3 (30) | Autosomal dominant inheritance | TAAD | Reduced SMC density through impairing development and increasing apoptosis |
| LOX (34, 35) | Genetic predisposition in 25% of familial TAAD | TAAD | Deficiency of LOX or inhibition of lysyl oxidases |
| MAT2A (31) | Strong familial association | TAAD | Defective MAT IIA enzyme impairs methylation reactions in SMC |
| MFPAP5 (32) | Strong familial association | TAAD | Mutation dysregulates TGFβ/BMP signalling pathway |
| MYH11 (36) | Strong familial association | TAAD | Upregulation of IGF-1 and angiotensin II without increased TGF |
| MYLK (37) | Strong familial association | TAD | Disruption of calmodulin and kinase activity of SMC |
| PRKG1 (38, 39) | Strong familial association | TAD | Increased PKG1 decreases contractility of aorta SMC |
| SMAD3 (40) | Responsible for 2% of TAAD | TAAD | SMAD3 haploinsufficiency disrupts differentiation and collagenous function of myofibroblasts |
| AAT1/FAA1 (41) | Genetic predisposition | TAAD | Identified association with loci at chromosome 11q23.2-q24 |
| AAT2/TAAD1 (42) | Genetic predisposition | TAAD | Identified association with loci at chromosome 5q13-14 |
| Unidentified gene (43) | Genetic predisposition | TAAD | Marfan-like condition associated with loci at chromosome 3p24-25 |

SMC, smooth muscle cell; TAA, thoracic aortic aneurysm; TAD, thoracic aortic dissection; PKG-1, type I cGMP-dependent protein kinase.
by the ECM, containing layers of structural proteins such as elastic lamellae and collagen fibre, as well as fibronectin and laminin, SMCs and glycosaminoglycans (7, 57, 58). TAAD is histologically characterised by the degeneration of elastic fibres, remodelling of collagen matrix, loss of SMC and pooling of glycosaminoglycans (59). As each of these are an integral component of the aortic wall, their dysfunction can lead to markedly reduced distensibility and long-term stability, leading to aneurysms and dissections (60).

To maintain vascular function, the aortic wall must be able to accommodate rhythmic pressure rises exerted by ventricular contractions. The luminal pressure is translated into circumferential and axial stress, at approximately 150 kPa, and is drastically increased in aneurysms which surpasses 450 kPa (60). Normally, under a high pressure, the aortic wall deforms isochorically and stretches, with stiffness directly proportional to the strain on the aorta. When aneurysms occur, the wall stiffness no longer varies and results in an increased distensibility and aortic compliance whereby the loss of stretching or wall stiffness at high pressure loci increases likelihood of aneurysm and dissection formation (60).

**Elastin, collagen and smooth muscle cells**

Elastic fibres of tunica media is made of several structural proteins such as elastin and fibrillin, both of which are central to elastogenesis and longer term stability of the fibre itself (61). As their deposition occurs perinatally, damage to elastin leaves a lasting impact due to the lack of further repair mechanisms after puberty (62, 63). Degradation and fragmentation of these elastic fibres reduces aortic resilience, compliance and distensibility and can be caused by a combination of mechanical wear and tear over a lifetime and inflammatory degradation via MMP upregulation (63, 64). Apart from elastic fibres, collagen is also involved in aortic wall pathologies. The collagen present is type I and III, which are responsible for strength and stiffness by acting as a protective sheath to bear majority of circumferential and axial stress during high pressure in addition to shielding the vascular SMC from excessive stress (65). Loss of these collagen would also lead to instability and predisposes the aorta to rupture (60). Unlike elastin, collagen has a much shorter half-life as active degradation and deposition allows structural adaptation to occur, making it less prone to mechanical wear and tear (66). However, it can still be affected by defective genes, expression and arrangement which compromises aortic wall strength and lead to stiffness (67).

Pathologies that affect elastic fibre and collagen predisposes a person to TAAD, as demonstrated by the aortic fragility in EDS where collagen type III is affected (12, 60). Increasingly disorganised collagen and fragmented elastic fibre is seen in both physiological ageing and in TAAD, leading to the loss of stiffness variation along the aorta. The resultant aorta is then unable to modulate and cope with the blood pressure and wall stress, leading to aneurysm and dissection risks (67).

The development of TAAD can be attributed to compromised wall integrity, a combined consequence of compromised aortic wall integrity and impaired repair mechanisms. Central to these processes are SMCs and adventitial fibroblasts which deposit and organise the ECM to maintain a physiological pressure and respond to haemodynamics changes (60). Each type of cell utilises different integrins, a class of transmembrane proteins responsible for bind to constituent parts of the ECM (68). Deficiency in integrins reduces the ability for cells-to-bind effectively to the ECM which leads to an overall reduction in contractile force (68).

**Glycosaminoglycans**

While loss of elastin, SMC dysfunction and collagen remodelling is common to all aneurysms, only TAD leads to glycosaminoglycans (GAG) pooling (69). The structural changes in TAAD are not limited to elastic and collagen fibres but also uniquely includes the accumulation of glycosaminoglycans which increases the risk of delamination and ruptures. GAGs are negatively charged repeating disaccharide units that are often overlooked as a contributor to TAAD due to their association with compression rather than tension (59, 69, 70). Compressive stress in the aorta is comprised solely of radial stress at approximately 10 kPa and peaks at 60 kPa when pressure distribution is asymmetrical along the aorta, providing a stark contrast to axial and circumferential stresses of 150 kPa (60, 69).

GAGs often accumulate in regions where elastic fibres and SMCs have degenerated, leading to a phenomenon called GAG pooling. This produces excessive pressure via the Donnan effect, where the equilibrium is affected by an electrostatic gradient established by the negatively charged GAGs (69, 70). The ionic gradient changes regional distribution of interstitial water, producing a swelling pressure of magnitude possibly exceeding axial and circumferential stress and is dependent on the charge density within the region (59). This leads to three distinct phenomena: separation of elastic lamina,
loss of wall tensile capacity and non-uniform stress distribution along the aorta. The swelling pressure caused by ion gradient contributes to the separation of elastic lamellae from media, as demonstrated by Lesauskaite et al. where an increased separation distance of elastic lamellae is observed at areas of pooled GAGs (58, 59). This renders the aortic wall vulnerable to subsequent dissection and rupturing. Donnan swelling also affects SMC interactions with elastic fibres of the media, impacting SMC mechanotransduction and thus affecting various signalling pathways of ECM metabolism, resulting in deleterious effect of hemostasis and homeostasis (69, 70). Loss of tensile capacity occurs as GAGs displace elastic fibres, collagen and SMC, interrupting regular function. This essentially replaces tensile carrying molecules and increases compressive capabilities at the cost of tensile capacity, manifesting as reduced maximum axial and circumferential load before dissection occurs (58). Finally, GAG pooling at specific regions result in the geometric discontinuity and irregularity along the aorta, giving rise to focal stress concentration where local pressures can increase by several fold (58, 69, 70). In some instances, as seen in MFS, additional aortic wall stiffening, elastic fibre fragmentation and collagen remodelling can exacerbate the effects of irregular stress distribution (65).

Inflammation of the aortic wall

In addition to genetics, inflammatory component of TAAD should also be considered to better understand the role of immunological effector cells in medial degeneration. Pro-inflammatory cells are central to the pathophysiology and express cytokines that directly trigger aortic wall degradation through events such as SMC apoptosis and ECM proteolysis.

Mechanics of inflammation

The underlying trigger of inflammatory aetiology of TAAD is still debated. Some hypothesise that the presence of excess lipids in the aorta increases the number of inflammatory cells: the inflammatory response to lipids, or a product of lipid oxidation, results in degradation of the media and hence increases the risk of TAAD (71, 72). Others have found that autoimmune reactions produce aortic aneurysms based on the established correlation between inflammatory aortic aneurysms and autoimmune diseases (73). While the trigger is yet to be uncovered, active research continues to unravel the mechanisms involved.

Under physiological stress observed in TAAD, apoptotic and inflammatory signalling pathways are activated in aortic cells. Moreover, the pro-inflammatory state, and presence of apoptotic SMCs, drives inflammatory cells such as lymphocytes and macrophages to infiltrate the tunica media via the adventitia (74). This results in the destruction of wall structures as well as progressive enlargement of aorta which predisposes rupture and dissection. Apoptotic SMCs play a role in recruitment of such cells, as well as secretion of pro-inflammatory proteases, such as elastase and collagenase, that facilitate degradation of ECM (74, 75).

Cytokines

Inflammatory cells that infiltrate the aortic media secrete various inflammatory mediators such as interleukins (IL) and tissue necrosis factor alpha (TNFA) (72, 76, 77). Together with these effector cells, the mediators upregulate matrix metalloproteinase (MMP) expression, including MMP1, MMP2 and MMP9, which are known to degrade elastin. Additionally, MMP3 has been observed to have a collagenolytic role in TAAD and AAA (78, 79, 80). This results in medial degeneration and subsequently leads to dissection (74, 81). IL3 secreted by T lymphocytes, mast cells, CD19+ B lymphocytes and SMCs stimulates the production and secretion of MMP12 also known to degrade ECM (81). TNFA and interferon gamma (IFNG) are secreted by infiltrating lymphocytes which stimulate macrophage pro-inflammatory functions and upregulate MMP secretion, causing ECM remodelling (72, 79, 82). Other released pro-inflammatory molecules include reactive oxygen species that impairs endothelial functions and progresses development of cardiovascular disorders by breaking down structural components of tunica media (80, 83).

Transforming growth factor beta

A key cytokine involved in mediating aortic stability is transforming growth factor beta (TGFβ), a family of molecules with seemingly conflicting effects on TAAD development. TGFβ is a superfamily of ligands known to affect matrix degradation and vascular remodelling, causing the myriad of cardiovascular malfunctions in diseases such as MFS and LDS (77, 84, 85).
Its effects manifest via activation of various signalling pathways, both SMAD dependent and independent. As a whole, TGFβ regulates the function of SMCs and endothelial cells, including proliferation, migration and matrix metabolism (85, 86).

Sources demonstrate TGFβ as a significant molecule involved in the hallmark features of TAAD, particularly in those with MFS and LDS (84, 87). For example, TGFβ1 is thought to promote TAAD development and is found elevated in human and animals with aortic aneurysm (88). This results in the degeneration of ECM through MMPs and stimulation of collagen production, both of which are traits exhibited in TAD patients (75). TGFβ releases MMP2 and 9, resulting in further elastin degeneration, while MMP3 degrades collagen resulting in similar consequences (79, 80, 89). TGFβ is also observed to decrease contractile protein expression in thoracic aorta SMC and fibrillin assembly of the ECM, reducing aortic distensibility and elastic fibre numbers.

However, observations of increased TGFβ signalling in aortic aneurysm tissue lacks direct evidence supporting TGFβ activity as the underlying mechanism of TAAD and causality is yet to be established (84, 90). The elevation of TGFβ may be considered a homeostatic response to limit aorta damage: SMC expression of TGFβ in murine aortic tissue displays protective effects by limiting aortic aneurysm expansion in early MFS development (91, 92). More recent clinical research has shown TGFβ signalling to be protective against thoracic aorta dilatation and aneurysms. A study by Theruvath et al. associated the expression of TGFβ with a downregulation of MMPs and upregulation of MMP inhibitors such as TIMPs, resulting in decreased medial degeneration (93). Hence, while TGFβ signalling suppresses pro-inflammatory activity and reduces degenerative processes, its overexpression causes an accumulation of SMC, collagen and elastin which resembles the histological characteristics seen in TAAD (90).

In addition to aneurysms, there are also studies that recognise mutations of TGFβ as the cause of associated syndromes such as MFS and LDS. Mutation within the TGFβ signalling network of proteins such as FBN1 results in LDS and MFS, while mutations in TGFβ receptor structure also lead to TAAD (77, 87, 94). For instance, mutations in TGFβ3 genes cause a loss of TGFβ3 function and is a feature heavily associated with TAAD and mitral valve diseases (94). Moreover, a systemic blockade of TGFβ signalling pathway is shown to significantly increase aneurysm risk and severity while neutralisation of TGFβ via angiotensin II results in fatal aortic dissection (90, 95). Regardless of its effect, TGFβ is an essential component of stable vascular development. With different studies expressing contrasting opinions on the role of TGFβ, further research is required to determine its exact role in TAAD formation. The most recent literature on TGFβ and findings are displayed in Table 3.

Overall, a pro-inflammatory environment accompanied by death of SMCs reduces ECM homeostasis and decreases maintenance of the aortic wall (96). Avascular SMC ages and calcifies, it bears the mark of senescence whereby mitosis plateaus and pro-inflammatory cytokines are increased drastically (97). The senescence of SMC is another feature typically in aneurysmal vasculature: Once induced by stress signals and reactive oxygen species, secretion of pro-inflammatory cytokines follow and leads to medial degradation (98, 99). It is further observed that senescent cells may influence non-senescent cells to exhibit similar pro-inflammatory behaviour as well (100). This all results in aortic inflammation and weakens the wall (8, 75). Additionally, the degradation of the aortic media induces strong leukocyte chemotactic signals, promoting local inflammatory cell infiltration and further

Table 3  Overview of the most recent literature on TGF-β and its association with TAAD.

| Author, year | Population (n) | Subject | Findings |
|--------------|----------------|---------|----------|
| Wang et al., 2017 (77) | 602 | Human | Reduction in SMAD4 impairs TGF-β signalling pathway is involved in progression of TAAD |
| Scola et al., 2014 (89) | 144 | Human | TGFβ2 single polymorphism is associated with TAAD in women |
| Bertoli-Avella et al., 2015 (94) | 43 | Human | TGFβ3 ligand causes syndromic aortic aneurysms |
| Yang et al., 2016 (84) | 51 | Murine | Decreased TGFβ receptor expression on SMC disrupt aortic wall homeostasis and cause TAAD |
| Angelov et al., 2017 (90) | 75 | Murine | Loss of TGFβ receptor expression on SMC accelerated various thoracic aorta pathologies |
| Hu et al., 2015 (101) | 28 | Murine | Loss of TGFβ receptor expression on SMC accelerated TAAD |
| Chen et al., 2016 (95) | 119 | Murine | TGFβ inhibition in presence of angiotensin II facilitates development and rupture of TAA |
release of pro-inflammatory cytokines, such as IL6 and TNFA, compounding the damage inflicted on the aorta.

Summary and future direction

The importance of TAAD has become increasingly relevant in recent years and further research into this subject is crucial to reduce morbidity and mortality. A myriad of factors are involved in the development and progression of TAAD, all of which will require further exploration to understand the interaction between factors. Genetic basis of TAAD can be traced back to a variety of genetic syndromes despite being occasionally associated with other genes. Alternatively, an inflammatory aetiology can play a role and is also affected by genes and telomere activity. Furthermore, fluid dynamics and biomechanical properties add complexity to their interactions. The resultant outcome typically revolves around the disruption of collagen and elastin metabolism as well as changes to endothelial cell and smooth muscle cell physiology. Despite increasing attention in this area, our current knowledge remains limited, with knowledge of aneurysms often extrapolated from literature on AAA and murine studies, which may not necessarily be applicable to TAAD.

Future research should aspire to conduct larger scale studies to examine thoracic aortic pathologies specifically and is feasible through increasing genetic screening of apparently unaffected and undiagnosed relatives of those who suffer TAAD. This would not only facilitate correlation between genes and TAAD incidence, but also its relationship with severity. With developments in gene therapy becoming increasingly feasible, the challenge now lies in identifying all the associated gene and individual pathogenesis mechanism which may eventually become therapeutic targets to address.

Conclusion

This review has explored the current research regarding different aspects of TAAD, all of which will require further exploration: the lack of studies specific to thoracic aorta hinders our knowledge on TAAD and must receive greater emphasis to improve our understanding. The process of genetic screening continue to gain popularity as awareness of TAAD increase, helping to both facilitate patient management as well as provide larger patient groups to further identify genes responsible for TAAD. With much of the aetiologies, such as TGFβ and effects of telomere length, still debated, it is crucial to conduct larger studies and reach a consensus. All-in-all, the ongoing debate on TAAD will continue to drive innovative research and improve our understanding.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

1. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. Journal of Intensive Care 2018 6 15. (https://doi.org/10.1186/s40560-018-0287-7)
2. Statistics O for N. Death Registrations Summary Tables - England and Wales [internet], 2017.
3. Milewicz DM & Ramirez F. Therapies for thoracic aortic aneurysms and acute aortic dissections: old controversies and new opportunities. Arteriosclerosis, Thrombosis, and Vascular Biology 2019 39 126–136. (https://doi.org/10.1161/ATVBAHA.118.310956)
4. Iselbacher EM, Cardenas CLL & Lindsay ME. Hereditary influence in thoracic aortic aneurysm and dissection. Circulation 2016 133 2516–2528. (https://doi.org/10.1161/CIRCULATIONAHA.116.097626)
5. Wu L. The pathogenesis of thoracic aortic aneurysm from hereditary perspective. Gene 2018 677 77–82. (https://doi.org/10.1016/j.gene.2018.07.047)
6. Mathur A, Mohan V, Ameta D, Gaurav B & Haranahalli P. Aortic aneurysm. Journal of Translational Internal Medicine 2016 4 35–41. (https://doi.org/10.1515/jtim-2016-0008)
7. Pinard A, Jones GT & Milewicz DM. Genetics of thoracic and abdominal aortic diseases. Circulation Research 2019 124 588–606. (https://doi.org/10.1161/CIRCRESAHA.118.312436)
8. Goldfinger JZ, Halperin JL, Martin ML, Stewart AS, Eagle KA & Fuster V. Thoracic aortic aneurysm and dissection. Journal of the American College of Cardiology 2014 64 1725–1739. (https://doi.org/10.1016/j.jacc.2014.08.025)
9. Milewicz DM, Prakash SK & Ramirez F. Therapeutics targeting drivers of thoracic aortic aneurysms and acute aortic dissections: insights from predisposing genes and mouse models. Annual Review of Medicine 2017 68 51–67. (https://doi.org/10.1146/annurev-med-100415-022956)
10. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. New England Journal of Medicine 2014 371 2061–2071. (https://doi.org/10.1056/NEJMoa1404731)
11. Howard DPJ, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM & Oram Vascular Study. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford vascular study. Circulation 2013 127 2031–2037. (https://doi.org/10.1161/CIRCULATIONAHA.112.000483)
Biomechanics of thoracic aortic disease
A Harky et al.

12 Milewicz DM & Regalado E. Heritable Thoracic Aortic Disease Overview [Internet]. GeneReviews®. Seattle: University of Washington, 1993.
13 Balmforth D, Harky A, Adams B, Yap J, Shipolini A, Uppal R & Bashir M. Is there a role for biomarkers in thoracic aortic aneurysm disease? *Thoracic and Cardiovascular Surgery* 2019 67 12–19. (https://doi.org/10.1016/j.tcs.2018.08.055-0)
14 Sallik I & Rawla P. Marfan syndrome [Internet]. StatPearls, 2019.
15 Dietz H. Marfan syndrome [Internet]. GeneReviews®, 1993.
16 Tan L, Li Z, Zhou C, Cao Y, Zhang L, Li X, Cianflone K, Wang Y & Wang DW. FBN1 mutations largely contribute to sporadic non-syndromic aortic dissection. *Human Molecular Genetics* 2017 26 4814–4822. (https://doi.org/10.1093/hmg/ddx360)
17 Gillis E, Kaspers M, Salfenin M, Timmermans J, Cheriec EC, Bekkers SC, Fransen E, De Die-Smulders CE, Loepf BL & Van Laer L. An FBN1 deep intronic mutation in a familial case of Marfan syndrome: an explanation for genetically unsolved cases? *Human Mutation* 2014 35 571–574. (https://doi.org/10.1002/humu.22540)
18 Putnam EA, Zhang H, Ramirez P & Milewicz DM. Fibillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractual arachnodactyly. *Nature Genetics* 1995 11 456–458. (https://doi.org/10.1038/ng1295-456)
19 Woolnough R, Dhawan A, Dow K & Walia JS. Are patients with Loes-Bietz syndrome misdiagnosed with Beals syndrome? *Genom Genomic and Precision Medicine* 2018 9 1739–1745. (https://doi.org/10.1161/CIRCRESAHA.113.020272)
20 Gazit Y, Jacob G & Grahame R. Ehlers–Danlos syndrome – type I collagenopathies. *American Journal of Medical Genetics: Part A* 2015 167A 2382–2387. (https://doi.org/10.1002/ajmg.a.37162)
21 Frank M, Albusson J, Ranque B, Golmard L, Mazzella JM, Bal-Theoleyre L, Fauret AL, Mirault T, Denarié N, Mousseaux E, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. European Journal of Human Genetics 2015 23 1657–1664. (https://doi.org/10.1038/ejhg.2015.32)
22 Howard C, Picca L, Smith T, Sharif M, Bashir M & Harky A. The bicuspid aortic valve: Is it an immunological disease process? *Journal of Cardiovascular Surgery* 2019 34 482–494. (https://doi.org/10.1011/jocs.14050)
23 Shankar RK & BACKELJUWE PF. Current best practice in the management of Turner syndrome. *Therapeutic Advances in Endocrinology and Metabolism* 2018 9 31–40. (https://doi.org/10.1177/2042018817746291)
24 Silberbach M, Roos-Hesslink JW, Andersen NH, Braverman AC, Tan L, Li Z, Zhou C, Cao Y, Zhang L, Li X, Cianflone K, Wang Y & Regalado ES, Reynolds CL, Bollee H, Jollondi G, Prakash SK, Kwartler CS, et al. FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. *Journal of Clinical Investigation* 2016 126 948–961. (https://doi.org/10.1172/JCI83778)
25 Guo DC, Dong L, Regalado ES, Santos-Cortez RL, Zhao R, Cai B, Veeraraghavan S, Prakash SK, Johnson RJ, Mullenburg A, et al. MAT2A mutations predispose individuals to thoracic aortic aneurysms. *American Journal of Human Genetics* 2015 96 170–177. (https://doi.org/10.1016/j.ajhg.2014.11.015)
26 Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosoian L, Ho-Tin-Noe B, Regalado E, Varret M, et al. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. *American Journal of Human Genetics* 2014 95 736–743. (https://doi.org/10.1016/j.ajhg.2014.10.018)
27 Takeda N, Morita H, Fujita D, Inuzuka R, Taniguchi Y, Imai Y, Hirata Y &Komuro I. Congenital contractual arachnodactyly complicated with aortic dilatation and dissection: case report and review of literature. *American Journal of Medical Genetics: Part A* 2015 167A 2382–2387. (https://doi.org/10.1002/ajmg.a.37162)
28 Guo DC, Regalado ES, Dong L, Xu K, Santos-Cortez RL, Arnaud P, Ren Z, Cai B, Hostetler EM, Moran R, et al. LOX mutations predispose to thoracic aortic aneurysms and dissections. *Circulation Research* 2016 118 928–934. (https://doi.org/10.1161/CIRCRESAHA.115.307130)
29 Lee VS, Halabi CM, Hoffmann EP, Carmichael N, Leshchiner I, Veugelers M, Henderson K, Guo DC, Veugelers J, Komuro I. A deleterious MYH11 mutation causing familial thoracic aortic aneurysms and dissections. *Human Genome Variation* 2015 2 15028. (https://doi.org/10.1186/s12881-018-0769-7)
30 Takeda N, Morita H, Fujita D, Inuzuka R, Taniguchi Y, Nawata K & Komuro I. A deleterious MYH11 mutation causing familial thoracic aortic dissection. *American Journal of Human Genetics* 2015 96 170–177. (https://doi.org/10.1016/j.ajhg.2014.11.015)
31 Takeda N, Morita H, Fujita D, Inuzuka R, Taniguchi Y, Nawata K & Komuro I. A deleterious MYH11 mutation causing familial thoracic aortic dissection. *American Journal of Human Genetics* 2015 96 170–177. (https://doi.org/10.1016/j.ajhg.2014.11.015)
32 Shalata A, Mahroom M, Milewicz DM, Limin G, Kassum F, Badarna K, Tarabeih N, Assy N, Fell R, Cohen H, et al. Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype. *Orphanet Journal of Rare Diseases* 2018 13 41. (https://doi.org/10.1186/s13023-018-0769-7)
33 Zhang W, Han Q, Liu Z, Zhou W, Cao Q & Zhou W. Exome sequencing reveals a de novo PRKG1 mutation in a sporadic patient with aortic dissection. *BMC Medical Genetics* 2018 19 218. (https://doi.org/10.1186/s12881-018-0735-1)
34 Shankar S, Regalado ES, Guo DC, Milewicz DM & Montalcalio Aortic Consortium. The natural history of type B aortic dissection in patients with PRKG1 mutation c.530G>A (p.Arg177Gln). *Journal of Vascular Surgery* 2019 70 718–723. (https://doi.org/10.1016/j.jvs.2018.12.032)
35 Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, Clarke L, Bernstein F, Santos-Cortez RL, Leal SM, et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. *Circulation Research* 2011 109 680–686. (https://doi.org/10.1161/CIRCRESAHA.111.248161)
36 Vaughan CJ, Casey M, He J, Veugelers M, Henderson K, Guo D, Campagna R, Roman MJ, Milewicz DM, Devereux RB, et al.
Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation 2001 103 2469–2475. (https://doi.org/10.1161/01.cir.103.20.2469)

42 Guo D, Hasham S, Kuang SQ, Vaughan CJ, Boerwinkle E, Chen H, Abuelo D, Dietz HC, Basson CT, Shete SS, et al. Familial thoracic aortic aneurysms and dissections genetic: heterogeneity with a major locus mapping to 5q13-14. Circulation 2001 103 2461–2468. (https://doi.org/10.1161/01.cir.103.20.2461)

43 Milewicz DM, Chen H, Park E-SS, Petty EM, Zaghi H, Shashidhar G, Willing M & Patel V. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. American Journal of Cardiology 1998 82 474–479. (https://doi.org/10.1016/s0002-9149(98)00364-6)

44 Aschacher T, Salameh O, Enzmann F, Messner B & Bergmann M. Telomere biology and thoracic aortic aneurysm. International Journal of Molecular Sciences 2017 19 1E. (https://doi.org/10.3390/ijms19010003)

45 Bianchessi V, Badi I, Bertolotti M, Nigro P, D’Alessandra Y, Capogrossi MC, Zanobini M, Pompilio G, Raccic A & Lauri A. The mitochondrial IncRNA ASncmRNA-2 is induced in aging and replicative senescence in Endothelial Cells. Journal of Molecular and Cellular Cardiology 2015 81 62–70. (https://doi.org/10.1016/j.ymjcc.2015.01.012)

46 Boe AE, Eren M, Murphy SB, Murphy M, McAnally D, Smith LH, Miyata T & Vaughan DE. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates N-terminal pro-bradykinin in atherosclerosis. Journal of Vascular Research 2014 50 1–10. (https://doi.org/10.1159/000342436)

47 Humphrey JD, Schwartz MA, Tellides G & Milewicz DM. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. Circulation Research 2015 116 1448–1461. (https://doi.org/10.1161/CIRCRESAHA.114.304956)

48 Lin C-HH & Lilly B. Notch signaling governs phenotypic modulation of smooth blood leukocytes are associated with a high risk of ascending aortic aneurysms compared to healthy nonaneurysmal aortas. Atherosclerosis 2011 211 2871–2875. (https://doi.org/10.1016/j.atherosclerosis.2011.11.035)

49 Caoferi G, Parodi F, Pistorio A, Bertolotti M, Ventura F, Gambini C, Bianco P, Dallegri F, Pistoia V, Pezzolo A, et al. Endothelial and smooth muscle cells interactions in atherosclerosis. Frontiers in Cardiovascular Medicine 2018 5 151. (https://doi.org/10.3389/fcmov.2018.00151)

50 Lin C-HH & Lilly B. Notch signaling governs phenotypic modulation of smooth muscle cells. Vascular Pharmacology 2014 63 88–96. (https://doi.org/10.1016/j.vph.2014.09.004)

51 Cahill D, van der Voort PH, Wilson WR, Brown I, Humphrey JD, Egeblad M, Rodriquez M & Laurent TC. Mechanical elastin and collagen fibre microstructure of the human aorta in ageing and disease: a review. European Heart Journal 2008 29 2689–2694. (https://doi.org/10.1002/eurheartj.10836)

52 Blundar S, Messner B, Aschacher T, Zeller I, Türkcan A, Wiedemann D, Andreas M, Bläschke G, Lauber F, Schachter T, et al. Characteristics of TAV- and BAV-associated thoracic aortic aneurysms – smooth muscle cell biology, expression profiling, and histological analyses. Atherosclerosis 2012 220 355–361. (https://doi.org/10.1016/j.atherosclerosis.2011.11.035)

53 Hsuuks T, Santaniemi M, Kakko S, Taskinen P, Ukko O, Kesäniemi YA, Savolainen MJ & Salomunni T. Long telomeres in blood leukocytes are associated with a high risk of ascending aortic aneurysm. PLoS ONE 2012 7 e50826. (https://doi.org/10.1371/journal.pone.0050826)

54 Balisterri CR, Pisano C, Merlo D, Fattouch K, Caruso M, Incalcaterra E, Colonna-Romano G & Candore G. Is the mean blood leukocyte telomere length a predictor for sporadic thoracic aortic aneurysm? Data from a preliminary study. Rejuvenation Research 2012 15 170–173. (https://doi.org/10.1089/rej.2011.1273)

55 Yan J, Yang Y, Chen C, Peng J, Ding H & Wang DW. Short leukocyte telomere length is associated with aortic dissection. Atherosclerosis 2011 211 2871–2875. (https://doi.org/10.2169/internalmedicine.50.5958)

56 Chester AH, El-Hamamsy I, Butcher JT, Latifi N, Bertazzo S & Yacoub MH. The living aortic valve: From molecules to function. Global Cardiology Science and Practice 2014 52–77. (https://doi.org/10.5339/gcspr.2014.11)

57 Roccabianca S, Bellini C & Humphrey JD. Computational modelling suggests good, bad and ugly roles of glycosaminoglycans in arterial wall mechanics and mechanobiology. Journal of the Royal Society, Interface 2014 11 20140397. (https://doi.org/10.1098/rsif.2014.0397)

58 Humphrey JD, Schwartz MA, Tellides G & Milewicz DM. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. Circulation Research 2015 116 1448–1461. (https://doi.org/10.1161/CIRCRESAHA.114.304956)

59 Thomson J, Singh M, Eckersley A, Cain SA, Sherratt MJ & Baldock C. Fibrillin microfibrils and elastic fibre proteins: functional interactions and extracellular regulation of growth factors. Seminars in Cell and Developmental Biology 2019 89 109–117. (https://doi.org/10.1016/j.semcdb.2018.07.016)

60 Yangagawa S & Wagensel J. Elastic fibers and biomechanics of the aorta: insights from mouse studies. Matrix Biology 2019 19. (https://doi.org/10.1016/j.matbio.2019.03.001)

61 Coccioalone AJ, Hawes JZ, Staiacuence M, Johnson EO, Murshed M & Wagensel JE. Elastin, arterial mechanics, and cardiovascular disease. American Journal of Physiology: Heart and Circulatory Physiology 2018 315 H189–H205. (https://doi.org/10.1152/ajpheart.00087.2018)

62 Wang M, Kim SH, Monticone RE & Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension 2015 65 698–703. (https://doi.org/10.1161/HYPERTENSIONAHA.114.04318)

63 Ferruzzi J, Collins MJ, Yeh AT & Humphrey JD. Mechanical assessment of elastin integrity in fibrillin-1-deficient carotid arteries: implications for Marfan syndrome. Cardiovascular Research 2011 92 287–295. (https://doi.org/10.1093/cvr/cvr195)

64 Kühn T, Mezger M, Hauser I, GueLT, Handgretinger R, Bruckner-Tuderman L & Nyström A. Collagen VII half-life at the dermal-epidermal junction zone: implications for mechanisms and therapy of genodermatoses. Journal of Investigative Dermatology 2016 136 1116–1123. (https://doi.org/10.1016/j.jid.2016.02.002)

65 Tsimis A, Krawiec JT & Vorp DA. Elastin and collagen fibre microstructure of the human aorta in ageing and disease: a review. Journal of the Royal Society, Interface 2013 10 20121004. (https://doi.org/10.1098/rsif.2012.1004)

66 Lu H, Fagnant PM, Bookwalter CS, Joel P & Trybus KM. Vascular disease-causing mutation R258C in ACTA2 disrupts actin dynamics and interaction with myosin. PNAS 2015 112 E4168–E4177. (https://doi.org/10.1073/pnas.1507587112)

67 Roccabianca S, Ateshan GA & Humphrey JD. Biomechanical roles of medial pooling of glycosaminoglycans in thoracic aortic dissection. Biomechanics and Modeling in Mechanobiology 2014 13 13–25. (https://doi.org/10.1007/s10237-013-0482-3)

68 Cikachat F, Koch CD, Mead T, Galalattoto J, Willard BR, Emerton KB, Eagleton FS, Koch CD, Mead T, Galalattoto J, Willard BR, Emerton KB, Eagleton MJ. Massive aagregen and verican accumulation in thoracic aortic aneurysm and
dissection. *JCI Insight* 2018 3 97167. (https://doi.org/10.1172/jci.insight.97167)

71 Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, Doran AC & Vickers KC. *The Role of Lipids and Lipoproteins in Atherosclerosis* (Internet). Endotext. MDText.com, 2000.

72 Gu J, Hu J, Zhang HW, Xiao ZH, Fang Z, Qian H, Zhong MH, Guo YQ, Zhang EY, Shi YK, et al. Time-dependent changes of plasma inflammatory biomarkers in type A aortic dissection patients without optimal medical management. *Journal of Cardiothoracic Surgery* 2015 10 3. (https://doi.org/10.1186/s13019-014-0199-0)

73 Gu BH, Choi JC, Shen YH, Song LZ, Scheurer ME, Luong A, Linton MF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL. MMP17/MT4-MMP and its soluble receptors in the pathogenesis of thoracic aortic aneurysms: OPNing new potential for effective optimal medical management. *Journal of Cardiac Surgery* 2015 236 373–385. (https://doi.org/10.1002/jc.23534)

74 Wu D, Shen YH, Russell L, Coselli JS & LeMaire SA. Molecular mechanisms of thoracic aortic dissection. *Journal of Surgical Research* 2013 184 907–924. (https://doi.org/10.1016/j.jss.2013.06.007)

75 Johnston WF, Salmon M, Pope NH, Meher A, Su G, Stone ML, Lu G, Owens GK, Upchurch GR & Allawadi G. Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms. *Circulation* 2014 130 (11 Supplement 1) S51–S59. (https://doi.org/10.1161/CIRCULATIONAHA.113.006800)

76 Wang Y, Yin P, Chen YH, Yu XS, Ye WX, Huang HY, Ji ZC & Shen ZY. A functional variant of SMAD4 enhances macrophage recruitment and inflammatory response via TGF-β signaling in thoracic aortic aneurysm and dissection. *Aging* 2018 10 3683–3701. (https://doi.org/10.18632/aging.101662)

77 Papke CL, Yamashiro Y & Yanagisawa H. MMP17/MT4-MMP and thoracic aortic aneurysms: OPNing new potential for effective treatment. *Circulation Research* 2015 117 109–112. (https://doi.org/10.1161/CIRCRESAHA.117.306851)

78 Prasad K, Sarkar A, Zafar MA, Shoker A, Moselhi HE, Tranquilli M, Ziganshin BA & Elefteriades JA. Advanced glycation end products and inflammatory biomarkers in type A aortic dissection patients without optimal medical management. *Journal of Cardiothoracic Surgery* 2015 25 99–110. (https://doi.org/10.1002/jc.23515)

79 Patel K, Zafar MA, Ziganshin BA & Elefteriades JA. Diabetes mellitus: is it protective against aneurysm? A narrative review. *Cardiology* 2018 141 107–122. (https://doi.org/10.1159/000490373)

80 Liu C, Zhang C, Jia L, Chen B, Liu L, Sun J, Zhang W, You B, Li Y, Li P, et al. Interleukin-3 stimulates matrix metalloproteinase 12 production from macrophages promoting thoracic aortic aneurysm/dissection. *Clinical Science* 2018 132 655–668. (https://doi.org/10.1042/CS20171529)

81 Yamashiro Y & Yanagisawa H. Crossing bridges between extra- and intra-cellular events in thoracic aortic aneurysms. *Journal of Atherosclerosis and Thrombosis* 2018 25 99–110. (https://doi.org/10.5551/jat.17015)

82 Rao W, Morimoto K, Hasegawa T, Sasaki N, Yamashita T, Hirata K, Okita Y & Okada K. Oralily administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. *Journal of Vascular Surgery* 2014 59 1098–1108. (https://doi.org/10.1016/j.jvs.2013.04.048)

83 Yang P, Schmit BM, Fu C, DeSart K, Oh SP, Berceli SA & Jiang Z. Smooth muscle cell-specific Tgfb1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events. *Scientific Reports* 2016 6 35444. (https://doi.org/10.1038/srep35444)

84 Zeng L, Dang TA & Schunkert H. Genetics links between transforming growth factor β pathway and coronary disease. *Atherosclerosis* 2016 253 237–246. (https://doi.org/10.1016/j.atherosclerosis.2016.08.029)

85 Zhu SB, Zhu J, Zhou ZZ, Xi EP, Wang RP & Zhang Y. TGF-β1 induces human aortic vascular smooth muscle cell phenotype switch through PEJU/ALK/ID2 signaling. *American Journal of Translational Research* 2015 7 2764–2774.
Role of vascular smooth muscle cell phenotypic switching and calcification in aortic aneurysm formation. Arteriosclerosis, Thrombosis, and Vascular Biology 2019 39 1351–1368. (https://doi.org/10.1161/ATVBAHA.119.312787)

99 Katsuumi G, Shimizu I, Yoshida Y & Minamino T. Vascular senescence in cardiovascular and metabolic diseases. Frontiers in Cardiovascular Medicine 2018 5 18. (https://doi.org/10.3389/fcvm.2018.00018)

100 International Academy of Cardiology. International Academy of Cardiology Annual Scientific Sessions 2015 20th World Congress on Heart Disease – Abstracts (Internet). Karger, 2015.

101 Hu JH, Wei H, Jaffe M, Airhart N, Du L, Angelov SN, Yan J, Allen JK, Kang I, Wight TN, et al. Postnatal deletion of the Type II transforming growth factor-β receptor in smooth muscle cells causes severe aortopathy in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2015 35 2647–2656. (https://doi.org/10.1161/ATVBAHA.115.306573)

Received in final form 19 September 2019
Accepted 15 October 2019
Accepted Preprint published online 15 October 2019